Bunyavirus SFTSV exploits autophagic flux for viral assembly and egress.

Autophagy

State Key Laboratory of Virology, School of Public Health, Wuhan University, Wuhan, China.

Published: July 2022

Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging negatively stranded enveloped RNA bunyavirus that causes SFTS with a high case fatality rate of up to 30%. Macroautophagy/autophagy is an evolutionarily conserved process involved in the maintenance of host homeostasis, which exhibits anti-viral or pro-viral responses in reaction to different viral challenges. However, the interaction between the bunyavirus SFTSV and the autophagic process is still largely unclear. By establishing various autophagy-deficient cell lines, we found that SFTSV triggered RB1CC1/FIP200-BECN1-ATG5-dependent classical autophagy flux. SFTSV nucleoprotein induced BECN1-dependent autophagy by disrupting the BECN1-BCL2 association. Importantly, SFTSV utilized autophagy for the viral life cycle, which not only assembled in autophagosomes derived from the ERGIC and Golgi complex, but also utilized autophagic vesicles for exocytosis. Taken together, our results suggest a novel virus-autophagy interaction model in which bunyavirus SFTSV induces classical autophagy flux for viral assembly and egress processes, suggesting that autophagy inhibition may be a novel therapy for treating or releasing SFTS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298452PMC
http://dx.doi.org/10.1080/15548627.2021.1994296DOI Listing

Publication Analysis

Top Keywords

bunyavirus sftsv
12
flux viral
8
viral assembly
8
assembly egress
8
classical autophagy
8
autophagy flux
8
sftsv
6
autophagy
5
bunyavirus
4
sftsv exploits
4

Similar Publications

Background: Severe fever with thrombocytopenia syndrome (SFTS) is a rapidly progressive infectious disease triggered by a novel bunyavirus (SFTSV). Despite the critical role of host lipid metabolism in viral infections, research on dyslipidemia in SFTS remains limited.

Methods: This retrospective study included 433 SFTS patients, who were stratified into survival group (n = 365) and death group (n = 68) and who were treated at the Shandong Public Health Clinical Center from September 2021 to December 2023.

View Article and Find Full Text PDF

N6-methyladenosine RNA modification promotes Severe Fever with Thrombocytopenia Syndrome Virus infection.

PLoS Pathog

November 2024

Jiangsu Key Laboratory of Infection and Immunity, MOE Key Laboratory of Geriatric Diseases and Immunology, The Forth Affiliated Hospital of Soochow University, Institutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China.

Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV), a novel bunyavirus primarily transmitted by Haemaphysalis longicornis, induces severe disease with a high mortality rate. N6-methyladenosine (m6A) is a prevalent internal chemical modification in eukaryotic mRNA that has been reported to regulate viral infection. However, the role of m6A modification during SFTSV infection remains elusive.

View Article and Find Full Text PDF

Unlabelled: Severe fever with thrombocytopenia syndrome (SFTS) is a rapidly progressing infectious disease caused by a novel bunyavirus characterized by high fever, thrombocytopenia, and multiple organ damage. While lipids play an important role in viral infections, the specific alterations in lipid metabolism during SFTSV infection remain unclear. This study aimed to elucidate the global lipid metabolic profiles of SFTS patients with mild, severe, and fatal outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Severe fever with thrombocytopenia syndrome (SFTS) is a serious infectious disease linked to a novel bunyavirus, and this study focuses on understanding how lipid metabolism changes during early SFTSV infection.
  • The researchers collected blood samples from patients with severe and mild SFTS, as well as healthy controls, to analyze lipid differences and correlations with clinical outcomes.
  • The results show significant dysregulation of lipids in SFTS patients, with notable increases and decreases in specific lipids compared to healthy individuals, shedding light on potential mechanisms and paving the way for improved diagnosis and treatment options.
View Article and Find Full Text PDF

Molecular mechanism and structure-guided humanization of a broadly neutralizing antibody against SFTSV.

PLoS Pathog

September 2024

State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, China.

Article Synopsis
  • Severe fever with thrombocytopenia syndrome virus (SFTSV) is a new tick-borne virus with a high mortality rate (up to 30%) that causes severe fever and thrombocytopenia syndrome (SFTS).
  • The study focuses on a monoclonal antibody, mAb 40C10, which can neutralize various SFTSV genotypes; researchers identified a specific binding epitope within the virus's glycoprotein N, enhancing understanding of how the antibody works.
  • The researchers also humanized mAb 40C10 to make it less likely to provoke an immune response in humans, resulting in antibodies that maintained strong efficacy; one exhibited significant therapeutic potential in mouse models, paving the
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!